PMID- 32744827
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20210817
IS  - 1558-2035 (Electronic)
IS  - 1558-2027 (Linking)
VI  - 21
IP  - 9
DP  - 2020 Sep
TI  - Do the remodeling effects of sacubitril/valsartan treatment depend upon heart 
      failure duration?
PG  - 682-687
LID - 10.2459/JCM.0000000000001000 [doi]
AB  - AIMS: The angiotensin receptor and neprilysin inhibitor (ARNI) 
      sacubitril/valsartan (LCZ696) is recommended for the treatment of patients with 
      heart failure in New York Heart Association (NYHA) class II-III and left 
      ventricular ejection fraction (LVEF) 35% or less. We examined the effects of 
      sacubitril/valsartan on cardiac remodeling and their correlation with heart 
      failure duration in patients enrolled in our heart failure clinic from March 2017 
      to December 2019. METHODS: Echocardiographic and clinical/laboratory data were 
      collected at baseline and at 6-month and 12-month follow-up visits in 69 patients 
      (age 67 +/- 12 years, disease duration 8.4 +/- 5.8 years, 93% men). RESULTS: At both 
      time points, mean NYHA class, NT-proBNP level, LVEF, LV end-systolic volume, and 
      estimated systolic pulmonary pressure significantly (P < 0.05) improved versus 
      baseline, as did the proportion of patients with diastolic dysfunction grade 3 or 
      functional mitral regurgitation grade 3-4. In the subgroup with mean disease 
      duration less than 8.5 years (n = 40), there was a significant improvement in all 
      variables at both time points; in this group, a recovery of right ventricular 
      function was also seen at the 12-month follow-up. On the contrary, patients with 
      heart failure duration of at least 8.5 years (n = 29) showed only a slight 
      improvement in LVEF and mitral regurgitation at 12 months. There were no 
      significant changes in renal function and/or potassium levels in all patients. 
      CONCLUSION: In patients with a relatively short disease duration, 
      sacubitril/valsartan was associated with a strong favorable remodeling of the 
      left ventricle and improvement in pulmonary circulation.
FAU - Villani, Alessandra
AU  - Villani A
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
FAU - Ravaro, Silvia
AU  - Ravaro S
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
AD  - Dipartimento di Medicina e Chirurgia, Universita di Milano-Bicocca, Milan, Italy.
FAU - Cerea, Paolo
AU  - Cerea P
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
AD  - Dipartimento di Medicina e Chirurgia, Universita di Milano-Bicocca, Milan, Italy.
FAU - Caravita, Sergio
AU  - Caravita S
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
FAU - Ciambellotti, Francesca
AU  - Ciambellotti F
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
FAU - Branzi, Giovanna
AU  - Branzi G
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
FAU - Munforti, Carlotta
AU  - Munforti C
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
FAU - Parati, Gianfranco
AU  - Parati G
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
AD  - Dipartimento di Medicina e Chirurgia, Universita di Milano-Bicocca, Milan, Italy.
FAU - Malfatto, Gabriella
AU  - Malfatto G
AD  - Istituto Auxologico Italiano IRCCS, Dipartimento di Scienze Cardiovascolari, 
      Neurologiche, Metaboliche, Ospedale S. Luca.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Med (Hagerstown)
JT  - Journal of cardiovascular medicine (Hagerstown, Md.)
JID - 101259752
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Protease Inhibitors)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
CIN - J Cardiovasc Med (Hagerstown). 2021 Mar 1;22(3):233-234. PMID: 32925393
CIN - J Cardiovasc Med (Hagerstown). 2021 Mar 1;22(3):234-235. PMID: 33136813
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminobutyrates/adverse effects/*therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use
MH  - Biphenyl Compounds/adverse effects/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Heart Failure/diagnostic imaging/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/diagnostic imaging/drug effects/physiopathology
MH  - Mitral Valve Insufficiency/diagnostic imaging/drug therapy/physiopathology
MH  - Neprilysin/antagonists & inhibitors
MH  - Protease Inhibitors/adverse effects/*therapeutic use
MH  - Pulmonary Circulation/drug effects
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Stroke Volume/*drug effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Valsartan/adverse effects/*therapeutic use
MH  - Ventricular Function, Left/*drug effects
MH  - Ventricular Function, Right/drug effects
MH  - Ventricular Remodeling/*drug effects
EDAT- 2020/08/04 06:00
MHDA- 2021/06/08 06:00
CRDT- 2020/08/04 06:00
PHST- 2020/08/04 06:00 [entrez]
PHST- 2020/08/04 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
AID - 01244665-202009000-00011 [pii]
AID - 10.2459/JCM.0000000000001000 [doi]
PST - ppublish
SO  - J Cardiovasc Med (Hagerstown). 2020 Sep;21(9):682-687. doi: 
      10.2459/JCM.0000000000001000.